Aurobindo Pharma has informed that Auro Vaccines, a wholly owned subsidiary of the Company, has entered into a Licence Agreement with Hilleman Laboratories Singapore, to develop, manufacture and commercialise a pentavalent vaccine candidate used in children vaccination.
The above information is a part of company’s filings submitted to BSE.